A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects

NCT04769479 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloidosis

Interventions

DRUG: acoramidis

Sponsor

Eidos Therapeutics, a BridgeBio company